Aimble is involved in the development of an AI-based platform for candidates of new drug substances, utilizing technologies like docking, AI, quantum calculation, and molecular dynamics simulation.

Aimble

Primordial AI utilizes evolutionary data and artificial intelligence to discover drug targets, focusing on achieving next-generation drug development.

Primordial AI

Aimble | 12 followers on LinkedIn. Aimble is a company based out of Seoul, South Korea.

Researcher on cheminformatics, bioinformatics, and pharmacoinformatics

Changwoo Lee

CEO at AIMBLE Inc.

Hyunjin Kim

성균관대학교 출신

권선화

Aimble 팀장

성현승

Drug discovery is a sequential process of target protein selection, drug design, in-vitro/in-vivo, pre-clinical, and clinical. During the whole process, drug design is the most important process because compounds selected from drug design are maintained till clinical, determining success or failure of the drug discovery. The drug design is so called computer-aided drug design (CADD), which has been ignored due to inaccuracy, slowness, and complexity of available computational tools for long times. However, introduction of AI (Artficial Intelligence) and high-performance GPU computer to CADD results in a great potential of CADD for drug discovery. So far AIMBLE has completed the development of a CADD platform, which includes binding affinity and toxicity solutions based on high-tech methods, i.e., molecular dynamics and quantum mechanics, as well as AI. The automated AIMBLE platform accomplishes structure-based drug design with great accuracy of Pearson correlation coefficient of 0.87 (binding affinity) and AUC of 0.9 (toxicity).

Metric
Company Name	Aimble	Primordial AI
Symbol
MSH ID	COM:AIMBLE	COM:PRIMORDIALBIO
Market	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services
Industry	Pharmaceuticals	Biotechnology
Country	KR	US
Stage
Employee Count
Website	aimble.com	primordialbio.com
LinkedIn	aimble	primordial-ai
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

AIMB

COM:AIMBLE

Aimble

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue